Week of July 16, 2012: Bristol-Myers Squibb Begins Tender Offer to Acquire Amylin Pharmaceuticals; FDA Approves Gilead's Truvada for Reducing the Risk of Acquiring HIV; and More - Pharmaceutical

Latest Issue

Latest Issue
PharmTech Europe

Week of July 16, 2012: Bristol-Myers Squibb Begins Tender Offer to Acquire Amylin Pharmaceuticals; FDA Approves Gilead's Truvada for Reducing the Risk of Acquiring HIV; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

BioStorage Technologies, a provider of sample-management solutions for the bioscience industry, including storage, cold-chain logistics, and virtual sample intelligence, is expanding its services to the Asia Pacific region. The expansion includes the appointment of Jason Huang as general manager of the region. BioStorage Technologies Asia Pacific will be headquartered in Singapore and will provide technical consulting in addition to a range of sample-management capabilities. Huang will be responsible for overseeing and managing the operations in Asia, identifying and developing new services, and driving overall business development and services growth in the region. Read More

Bristol-Myers Squibb (BMS) has begun a cash tender offer to purchase all outstanding shares of common stock of Amylin Pharmaceuticals. Upon the successful closing of the tender offer, stockholders of Amylin will receive $31.00 in cash for each share of Amylin common stock validly tendered and not validly withdrawn in the offer, without interest and less any applicable withholding taxes. Following the purchase of shares in the tender offer, Amylin will become a subsidiary of BMS. BMS had previously announced its intention to acquire Amylin on June 29, 2012. Read More

FDA has approved Gilead Sciences’s once-daily oral Truvada (emtricitabine; tenofovir disoproxil fumarate), a treatment to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. As part of the approval, Gilead worked with the FDA to develop a Risk Evaluation and Mitigation Strategy to help ensure safe use of Truvada for pre-exposure prophylaxis as part of a comprehensive prevention strategy. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here